The U.S. Food and Drug Administration today approved a device to help reduce the frequency of seizures in epilepsy patients who have not responded well to medications. The RNS Stimulator consists of a small neurostimulator implanted within the skull under the scalp. The neurostimulator is connected to one or two wires (called electrodes) that are … Read more
Asking patients with focal epilepsy (also known as partial seizures, which usually involve focal areas of the body and altered consciousness) how often they have seizures does not appear to provide an accurate count, according to a report in the November issue of Archives of Neurology, one of the JAMA/Archives journals. Reminding patients to record their seizures in a diary may not help, because patients may be unaware of some seizures.
The epilepsy drug lamotrigine is effective in controlling partial seizures when taken once a day as an added therapy, according to a study published in the October 16, 2007, issue of Neurology®, the medical journal of the American Academy of Neurology.
The U.S. Food and Drug Administration approved the first generic versions of Trileptal (oxcarbazepine), an anticonvulsant drug. Generic oxcarbazepine is FDA-approved for use alone or in combination with other medications in the treatment of partial seizures in adults and children aged four years and above.
New research from the Howard Florey Institute in Melbourne has shown why mutation in a single gene can cause epilepsy in infants. Infants are more susceptible to seizures because their brains are developing at a rapid rate, making their brain cells ‘excitable’. Their neurons are growing and making new connections with other nerve cells, which can disrupt normal brain activity and results in epilepsy.
GlaxoSmithKline (NYSE: GSK) announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the new drug application (NDA) for Lamictal®XR™ (lamotrigine) Extended-Release Tablets.
The University of Rochester Medical Center (URMC) is participating in a multi-center study of a new medical device to treat epilepsy. The Rochester study is being overseen by neurologists Michel Berg, M.D. and James Fessler, M.D., and neurosurgeons Web Pilcher, M.D., Ph.D. and Jason Schwalb, M.D.
A small device implanted in the skull that detects oncoming seizures, then delivers a brief electrical stimulus to the brain to stop them is under study at the Medical College of Georgia.
OVATION Pharmaceuticals, Inc. announced the initiation of a pivotal Phase III clinical trial evaluating clobazam, a unique 1,5 benzodiazapine with significant anticonvulsant properties, as adjunctive treatment for patients with Lennox-Gastaut syndrome (LGS), one of the most severe forms of childhood epilepsy that frequently persists into adulthood.
People with epilepsy who experience multiple auras, sensations such as a cold breeze or bright light before they have a seizure, may be good candidates for epilepsy surgery because their seizures seem to be coming from one area of the brain, according to a study published in the Aug. 21, 2007, issue of Neurology, the medical journal of the American Academy of Neurology.